Article Details
Retrieved on: 2022-02-18 18:16:46
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The trial included CSU patients who don't respond to biologic treatment, Novartis AG (NYSE: NVS) / Roche Holdings AG's (OTC: RHHBY) Xolair (omalizumab) ...
Article found on: www.benzinga.com
This article is found inside other Hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here